Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Mantle-Cell 11Lymphoma, Large B-Cell, Diffuse 5Leukemia, B-Cell 4Lymphoma 3Lymphoma, Non-Hodgkin 2Leukemia 2Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphatic Diseases 1Heart Failure 1

Interventions

venetoclax 22Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4Dexamethasone 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2Mycophenolic Acid 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia × acalabrutinib × Clear all
NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06520098 2025-10-14

Benefit VA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡